Track topics on Twitter Track topics that are important to you
Seattle Genetics (NASDAQ: SGEN), the developer of targeted cancer drugs, said today that it expects to finish this year with about $280 million of cash and investments in the bank, down slightly from the $295 million that it started with on New Year’s Day. The company said it expects to generate $40 to $45 million [...]
Original Article: SeaGen Expects $280M Cash at Year EndNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...